| Abstract ID | Presenting Author Name | Topic |
| ISBMT_P_001 | Shailesh Lavana | Plerixafor in two healthy donors –“Just in time”. |
| ISBMT_P_003 | Poornima Puttaraju | A Diagnostic quagmire initially that turned in to a success story |
| ISBMT_P_004 | Suvir Singh | Autologous transplantation for myeloma with dialysis dependent renal dysfunction: A practical approach |
| ISBMT_P_005 | Sudhir Kumar | Epistemology of Autologous Stem Cell Transplantation in adult Hodgkin Lymphoma at AIIMS |
| ISBMT_P_006 | Mayur Babasaheb Mundhe | Treosulfan based conditioning regimens in hematopoietic cell transplant: A single-centre experience |
| ISBMT_P_007 | Manthan Kathrotiya | Nocardiosis in post allogenic hematopoietic stem cell transplant recipients: a bug least suspected? |
| ISBMT_P_008 | Manthan Kathrotiya | Hemophagocytic lymphohistiocytosis following haploidentical allogenic stem cell transplantation – Fate of the furious? |
| ISBMT_P_009 | Sachin Punatar | Lenalidomide with or without dexamethasone for relapsed / refractory Hodgkin lymphoma post autologous stem cell transplant |
| ISBMT_P_010 | Mohini Mendiratta | Immune Reconstitution Following Hematopoietic Stem Cell Transplantation: A Study From AIIMS |
| ISBMT_P_011 | Shruti Bhise | Navigating a haploidentical hematopoietic stem cell transplant in a case of relapsed pre-b all with colostomy |
| ISBMT_P_012 | Megha Saroha | Patterns of relapse and outcomes in patients with acute leukemia post allogenic transplantation |
| ISBMT_P_013 | Ambreen Pandrowala | Excellent transplant outcomes in primary immunodeficiency children despite higher pediatric HCT- comorbidity index score |
| ISBMT_P_014 | Ambreen Pandrowala | Hematopoietic stem cell transplant for children with dedicator of cytokinesis 8 deficiency: single center experience with excellent outcomes |
| ISBMT_P_015 | ManasaKakunje | Blinatumomab for childhood relapse/refractory all in an indian paediatric setup |
| ISBMT_P_016 | Varsha Mishra | Increase in incidence of carbapenem resistant enterobacteriaceae (cre) colonization at referral to a pediatric transplant unit in mumbai |
| ISBMT_P_017 | Ambreen Pandrowala | Excellent outcomes in non-malignant disorders using Alemtuzumab serotherapy and T-cell capping for HLA matched graft |
| ISBMT_P_019 | Vineeta Gupta | Pediatric hematopoetic stem cell transplantation: Preliminary data from a transplant centre in Eastern Uttar Pradesh |
| ISBMT_P_020 | Annapoorani A | Second pediatric allogenic hematopoietic stem cell transplantation: case series |
| ISBMT_P_022 | Vigneshwar Venkatesan | The impact of a respiratory viral outbreak in a paediatric HSCT unit |
| ISBMT_P_025 | Sumathi S Hiregoudar | Granulocyte harvest by apheresis using medium‑molecular weight hydroxyethyl starch as a quality optimisation strategy-A single tertiary cancer care institution experience |
| ISBMT_P_026 | Malini Garg | Recombinant activated factor VII for refractory bleeding post stem cell transplant |
| ISBMT_P_029 | Minakshi Bansal | Allogeneic hematopoietic stem cell transplant for African sickle cell anemia patients – a single centre experience from North India |
| ISBMT_P_030 | Minit Shah | Omicron variant of SARS-CoV-2 Infection in Hematopoietic Stem Cell Transplant Recipients |
| ISBMT_P_031 | Giripunja M | Allogeneic Hematopoietic Stem Cell Transplantation in Aplastic Anemia, long term outcome in children and adults – A single centre experience |
| ISBMT_P_032 | Kaumil Patel | Cytokine Release Syndrome after Haploidentical Stem cell Transplant |
| ISBMT_P_034 | Nishant Jindal | Impact of Day 30 Immune Reconstitution on Outcomes in Patients undergoing Allogenic Stem Cell Transplant for Acute Leukaemia |
| ISBMT_P_035 | Nishant Jindal | Relevance of Vitamin D in Patients Undergoing HLA Matched Allogenic Stem Cell Transplant for Acute Leukaemia |
| ISBMT_P_036 | Annapoorani A | Outcome of Autologous Transplantation in high risk Neuroblastoma: Experience from a single center in South India |
| ISBMT_P_037 | VenkateswaranVellaichamy | Favorable outcomes of hematopoietic stem cell transplantation in children with rare red cell disorders using a treosulfan based conditioning regimen |
| ISBMT_P_038 | Suresh R Duraisamy | Hematopoietic Stem Cell Transplantation and Vaccine related infections in children with Inborn Errors of Immunity |
| ISBMT_N_010 | Praveen | Ewings sarcoma (PNET) with secondary AML and haploidentical HSCT |
Important Dates for Abstract Submissions
- Last date for abstract submission: March 09, 2022 (Midnight – IST)
- Notification of acceptance for oral/ e-poster presentations: March 15, 2022
- Submission of e-posters & videos for oral presentations: March 23, 2022
* It is mandatory for the presenting authors to register for the conference
The abstracts must be submitted in one of the following categories:
- Transplant Specific
- Paediatric HSCT Specific
- Nursing Specific
- Quality / Data Management Specific
Guidelines for Submission of Abstracts
- Maximum 500 words, which would not include the title of the abstract and author affiliations.
- All abstracts are subject to review by the Scientific Programme Committee and acceptance into the program is not guaranteed.
- Abstracts should be prepared and submitted as a Word document to abstracts@isbmt.org.
- ll abstracts must be accompanied by the Declaration Form from the presenting author
- Submission of the abstract carries with it an obligation to present the accepted abstract virtually without any change in scientific content during the allotted time at ISBMT 2022.
- Withdrawal of presentation should be intimated to the conference secretariat on or before March 19, 2022.
- If the application is not sent in the prescribed format, it will not be considered for review.
- Preference for oral or e-poster presentation may be indicated at the time of submission of abstract though the final decision of the scientific programme committee will be binding.
- Top 3 Oral and 3 e-posters respectively will receive the awards, details of which will be announced at the end of the meeting.
Abstract format
- The abstract may include one table or graph.
- Please use ‘Calibri’ font. The font size should be 11 points or bigger.
Abstract Title
Please write the title in Sentence Case. Do not use quotation marks.
(Example: The results of the research case study and its participants)
Leave one blank line between the title and authors/ affiliations.
Authors
The full names (no initials) of all participating authors must be included on the abstract. Please do not include degrees or professional titles.
The name of the presenting author should be underlined.
Author Affiliations
Please include the name of your organization, city, the state, and the country. Use a superscript number to link each author with their affiliation.
Abstract Text
Abstracts that merely state the results which will be presented will be subject to rejection.
The Committee suggests that the abstract follow the format outlined below.
- Aim
- Methods
- Results
- Conclusions
DECLARATION FORM
Conflict of Interest Statement
If the research described in the abstract was supported by a commercial company, you must indicate the company’s role in analysing the data or preparing the abstract.
- “No conflict of interest to disclose”
- This research was supported by __________. The company had no role in analysing the data or preparing the abstract.”
- “This research was supported by __________. The company inserts free text describing company role in data analysis or abstract preparation.”
Declaration form submitted by …………………………………………………….Date……………………………………………
